BTG (OTCMKTS:BTGGF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “BTG plc is a healthcare company. Its operating segment consists of Interventional Medicine and Specialty Pharmaceuticals. Interventional Medicine offers treatment of cancer, severe emphysema, severe blood clots and varicoseveins. Specialty Pharmaceuticals helps patients overexposed to certain medications or toxins. BTG plc is headquartered in London, the United Kingdom. “
BTG (OTCMKTS BTGGF) remained flat at $$10.23 during mid-day trading on Tuesday. BTG has a 12-month low of $6.74 and a 12-month high of $10.71.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.